| Literature DB >> 35069987 |
Ivana Okić-Đorđević1, Hristina Obradović2, Tamara Kukolj2, Anđelija Petrović2, Slavko Mojsilović2, Diana Bugarski2, Aleksandra Jauković2.
Abstract
Current research data reveal microenvironment as a significant modifier of physical functions, pathologic changes, as well as the therapeutic effects of stem cells. When comparing regeneration potential of various stem cell types used for cytotherapy and tissue engineering, mesenchymal stem cells (MSCs) are currently the most attractive cell source for bone and tooth regeneration due to their differentiation and immunomodulatory potential and lack of ethical issues associated with their use. The microenvironment of donors and recipients selected in cytotherapy plays a crucial role in regenerative potential of transplanted MSCs, indicating interactions of cells with their microenvironment indispensable in MSC-mediated bone and dental regeneration. Since a variety of MSC populations have been procured from different parts of the tooth and tooth-supporting tissues, MSCs of dental origin and their achievements in capacity to reconstitute various dental tissues have gained attention of many research groups over the years. This review discusses recent advances in comparative analyses of dental MSC regeneration potential with regards to their tissue origin and specific microenvironmental conditions, giving additional insight into the current clinical application of these cells. ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.Entities:
Keywords: Clinical application; Dental mesenchymal stem cells; Hypoxia microenvironment; Inflammatory microenvironment; Microenvironment; Modulation of regenerative potential; Tissue origin
Year: 2021 PMID: 35069987 PMCID: PMC8727232 DOI: 10.4252/wjsc.v13.i12.1863
Source DB: PubMed Journal: World J Stem Cells ISSN: 1948-0210 Impact factor: 5.326
Figure 1Schematic drawing illustrating sources of human dental tissue-derived mesenchymal stem cells. DFSCs: Dental follicle stem cells; DPSCs: Dental pulp stem cells; GMSCs: Gingival mesenchymal stem cells; PDLSCs: Periodontal ligament stem cells; SCAPs: Stem cells from the dental apical papilla; SHEDs: Stem cells from human exfoliated deciduous teeth.
Figure 2Properties of mesenchymal stem cells. mesenchymal stem cells are the population of multipotent stromal cells present in adult and perinatal tissues where they participate in maintaining of homeostasis. Due to their self-renewal capacity, differentiation potential into specialized cells of mesodermal origin and immunomodulatory features, these undifferentiated cells can be potentially applied in regenerative medicine and cell therapy.
Figure 3Functional properties and differences among dental mesenchymal stem cells. Dental mesenchymal stem cells (MSCs) are involved in dental tissues regeneration which is influenced by local microenvironment of the tissues they reside in. Overall, all dental MSCs represent good candidates for tissue regeneration, however their capacities differ (shown in table on the right). > , < and ~ represent higher, lower or similar capacity/rate respectively; The numbers in square brackets indicate the references. DFSCs: Dental follicle stem cells; DPSCs: Dental pulp stem cells; GMSCs: Gingival mesenchymal stem cells; PDLSCs: Periodontal ligament stem cells; SCAPs: Stem cells from the dental apical papilla; SHEDs: Stem cells from human exfoliated deciduous teeth.
Effects of different oxygen levels on regenerative potential of human dental mesenchymal stem cells
|
|
|
|
| DPSCs | ||
| < 1% O2 | Weak ALP activity, weak calcium deposition | Janjić |
| 2% O2 | Proliferation↑; odontogenic differentiation↑; angiogenesis↑; | Kuang |
| No change in proliferation; calcium deposits↑; proteoglycan deposition↑; lipid droplets↑; PPAR𝛾2 mRNA↑ | Zhou | |
| Proliferation↓; Runx2 mRNA expression↑ (both 2D and 3D conditions); Runx2 and Col1A mRNA expression, osteopontin in 2D culture↑, calcium deposition in 3D culture↑, calcium deposition in 2D culture↓ | Labedz-Maslowska | |
| 3% O2 | BMP2, OCN and RUNX2 protein expression↑; calcium deposits↑; RunX2 and Sp-7 mRNA expression↑; | Wu |
| 5% O2 | Proliferation↑; mineralization↑ | Kwon |
| PDLSCs | ||
| 1.5%-2% O2 | ALP activity↓; SPARC protein expression↓; ALP, OCN, and BMP-2 mRNA expression↓; proliferation↓ | Hou |
| 2% O2 | Calcium deposition, proteoglycan deposition↑; lipid droplets↑; Runx2, Sox9 mRNA expression↑ | Zhou |
| ALP activity↑; Runx2 and Sp7 mRNA and protein expression↑; mineralization↑ | Wu | |
| SPP1, RUNX2, SP7 mRNAs and protein expression↑ | Li | |
| Proliferation↑; RUNX-2 and ALP protein expression↑; no effect on adipogenic differentiation; | Yu | |
| Proliferation↑; Runx2, osteopontin and osteocalcin mRNA expression↑; | Zhang | |
| ALP activity↑; Runx2 mRNA expression↑ | Chen | |
| 3% O2 | Proliferation↑; osteogenic and adipogenic differentiation↓; chondrogenic differentiation↑; preconditioning: Osteogenic and adipogenic differentiation↑ | Murabayashi |
| Runx2, Alp, Col1, and Ocn mRNA expression↑; RUNX2 protein | Xu | |
| 5% O2 | ALP activity↓ | Matsuda |
| 5% O2; 1% O2 | Proliferation↓; ALP activity↑; Opn, Alp mRNA expression↑; Cemp1, Cap mRNA expression↑ | Xiao |
| 8% O2 | Proliferation↑; Cemp1, Ocn mRNA expression↑; CEMP protein expression↑; mineral deposition↑; ALP activity↑; | Choi |
| SHEDs | ||
| 1% O2 | Proliferation↑; mineralization↑; ALP activity↑; OPN and DMP1 protein expression↑; | Novais |
| 2.3% O2 | Proliferation↑; no effect on adipogenic and osteogenic differentiation | Kanafi |
| SCAPs | ||
| 1% O2 | No effect on proliferation; RunX2, Alp, TGF-1↑; neuronal differentiation (CNP, NSE, and SNAIL mRNA expression↑; angiogenesis (VEGF A and B)↑; adipocyte lipid binding protein (ALBP)↓ | Vanacker |
| 3% O2 | ALP activity↑; mineralization↑; Dspp, Dmp1 and Bsp mRNA expression↑ | Yang |
| Chemical hypoxia | ||
| DPSCs | ||
| 100 μM CoCl2 | No effect on proliferation; SOX9 and VCAN; no expression Col2a1, Acan↑, Col 10 mRNA expression↓; proteoglycans↓ | Teti |
| 100 mM CoCl2 | Short term: RUNX2, ALP, OCN, COL1A1 mRNA and protein expression↑; long term: RUNX2, ALP, OCN, COL1A1 mRNA and protein expression↓ | Zheng |
| ALP activity↓; Alp, Ocn, and Runx2 mRNA expression↓; mineralization↓ | Osathanon | |
| 200 μM CoCl2 | ALP activity↓; Runx2, Alp, Ocn and Col-1 mRNA and protein expression↓; mineralization↓ | Song |
| PDLCs | ||
| 200 μM; 400 μM CoCl2 | Proliferation↓; ALP, RUNX2, collagen I↓ | Dong |
| 1 mM DMOG | No effect on proliferation; COL1, RUNX2 and CEMP1 protein expression↑ | Li |
| 0, 5, 10, 20 μM deferoxamine | Proliferation↓; Runx2, Opn and Col1 mRNA expression↑; calcium deposition↑ | Mu |
| SHED | ||
| 50 or 100 μM CoCl2 | ALP activity↓; calcium deposition↓; Alp, Runx2, and ColI mRNA expression↓ | Chen |
↑ and ↓ represent increasing or decreasing effect, respectively. ACAN: Aggrecan; ALBP: Adipocyte lipid binding protein; ALP: Alkaline phosphatase; BMP-2: Bone morphogenetic protein 2; BSP: Bone sialoprotein; CEMP 1: Cementum protein 1; COL-1: Collagen-1; DMOG: Dimethyloxalylglycine; DMP1: Dentin matrix protein 1; DPSCs: Dental pulp stem cells; DSPP: Dentin sialophosphoprotein; OCN: Osteocalcin; OPN: Osteopontin; PDLSCs: Periodontal ligament stem cells; PPAR𝛾2: Peroxisome proliferator-activated receptor gamma; RunX2: Runt-related transcription factor 2; SCAPs: Stem cells from the dental apical papilla; SHEDs: Stem cells from human exfoliated deciduous teeth; Sox-9: SRY-box transcription factor 9; Sp-7: Osterix; SPARC: Secreted protein acidic and rich in cysteine; TGF-β: Transforming growth factor-beta; VEGF: Vascular endothelial growth factor.
Effects of inflammatory microenvironment on regenerative potential of human dental mesenchymal stem cells
|
|
|
|
| DPSCs | ||
| Irreversible pulpitis | No change in proliferation; no change in differentiation; not being able to supress CD3 proliferation; IDO activity↓ | Inostroza |
| Decayed and pain affected tissue | No change in immunophenotype; proliferation↓; Ca deposition↑, OCN and RunX2 protein expression↑; MAP2 and NeuN protein expression↓; IL-6 expression and IL-6- induced osteogenesis↑ | Park |
| Irreversible pulpitis | Population doubling time↓; STRO‑1, CD90, CD105 and CD146 levels↑; Ca deposition↓; OCN and RUNX2 mRNA expression↓; LPL and PPARγ2 mRNA expression↓; | Alongi |
| Severe periodontal disease | Proliferation↑; Stro-1+, CD146, SSEA-4 levels↑; Ca deposition↑, OCN, RUNX2 and mRNA expression↑ (also upon stimulation with proinflammatory cytokines IL-1β and TNF-α) | Tomasello |
| GMSCs | ||
| Severe periodontal disease | Proliferation↑; Stro-1+, CD146, SSEA-4 levels↑; Ca deposition↑, OCN, RUNX2 and mRNA expression↑ (also upon stimulation with proinflammatory cytokines IL-1β and TNF-α) | Tomasello |
| Dental plaque-induced gingival hyperplasia | Proliferation↑; Runx2 and OCN mRNA expression↓; ALP activity↓; PPARγ mRNA expression↓ | Li |
| PDLSCs | ||
| Chronic peridontitis | No change in Runx2, OCN and ALP mRNA expression; no change in PPARγ and aP2 mRNA expression; no change in proliferation; | Park |
| Chronic periodontitis | Proliferation↑; migration↑; Ca deposition↓, Runx2, ALP and OCN mRNA expression↓; no change in lipid droplets level and PPARγ mRNA expression | Tang |
| Periodontitis with alveolar bone loss | Proliferation↑; RUNX2 mRNA expression↓; PPARγ mRNA expression↓ | Liu |
| Chronic periodontitis | viability and proliferation↓ | Soheilifar |
↑ and ↓ represent increasing or decreasing effect, respectively. ALP: Alkaline phosphatase; aP2: Adipocyte protein 2; DPSCs: Dental pulp stem cells; GMSCs: Gingival mesenchymal stem cells; IDO: Indoleamine 2,3-dioxygenase; NeuN: Neuronal nuclei; OCN: Osteocalcin; PDLSCs: Periodontal ligament stem cells; PPAR𝛾2: Peroxisome proliferator-activated receptor gamma; RunX2: Runt-related transcription factor 2.